A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS) [Time Frame: Week 12]

Percentage of Participants Achieving Clinical Response at Week 12 Based on Modified Mayo Score (mMS) [Time Frame: Baseline, Week 12]

Percentage of Participants Achieving Symptomatic Remission at Week 12 [Time Frame: Week 12]

Percentage of Participants Achieving Endoscopic Improvement at Week 12 [Time Frame: Week 12]

Percentage of Participants Achieving Endoscopic Remission at Week 12 [Time Frame: Week 12]

Percentage of Participants With no Bowel Urgency at Week 12 [Time Frame: Week 12]

Percentage of Participants With no Abdominal Pain at Week 12 [Time Frame: Week 12]

Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score ≥170 at Week 12 [Time Frame: Week 12]

Change From Baseline in Disease-Specific Health-related Quality of Life (HRQoL) as Measured by IBDQ Total Score at Week 12 [Time Frame: Baseline and Week 12]

Change From Baseline in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12 [Time Frame: Baseline and Week 12]